A Pivotal Phase II Clinical Trial of Utidelone Injection Plus Capecitabine in HER2-negative Breast Cancer Patients With Brain Metastases

NCT06764940 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

120

Enrollment

INDUSTRY

Sponsor class

Conditions

HER2-negative Breast Cancer Patients With Brain Metastases

Interventions

DRUG: Utidelone
DRUG: Utidelone in combination with capecitabine
DRUG: Utidelone in combination with capecitabine
DRUG: Utidelone in combination with capecitabine

Sponsor

Biostar Pharma, Inc.